Esmeron®

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Anesthesia, GeneralNeuromuscular Blockade

Phase 2

Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024)

CompletedNCT00535743

Merck Sharp & Dohme LLCAnesthesia, General

Start: 2004-03-04End: 2004-07-20Updated: 2019-02-11

Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).

CompletedNCT03519854

Merck Sharp & Dohme LLCNeuromuscular Blockade

Start: 2002-12-01End: 2003-06-01Updated: 2019-04-02